Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Triamcinolone Acetonide Injectable Suspension
Triamcinolone Acetonide Injectable · 1 trial · 1 indication
A video image of the posterior segment structures of the eye was taken before instillation of the test product and after. An independent masked reader evaluated the images and graded the degree of visualization on a 5-point scale ranging from 1 to 4 and anchored at the ends by "Not Visible (0)" and "Clearly Delineated (4)." The mean difference was calculated, and a higher number indicated increased visibility.
| Arm | Type | Description |
|---|---|---|
| Triamcinolone | EXPERIMENTAL | Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal. |
| Name | Type | Description |
|---|---|---|
| Triamcinolone Acetonide Injectable Suspension | DRUG | Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal. |
Inclusion Criteria: * Patients planning to undergo pars plana vitrectomy with good vision in the non-surgery eye. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Patients under 18. * Patients with previous vitrectomy, elevated intraocular pressure (IOP) and/or history...